Author/Authors :
Lee، نويسنده , , Kyung-Hun and Hur، نويسنده , , Hyung-Seok and Im، نويسنده , , Seock-Ah and Lee، نويسنده , , Juhee and Kim، نويسنده , , Hwang-Phill and Yoon، نويسنده , , Young-Kwang and Han، نويسنده , , Sae-Won and Song، نويسنده , , Sang-Hyun and Oh، نويسنده , , Do-Youn and Kim، نويسنده , , Tae-You and Bang، نويسنده , , Yung-Jue and Kim، نويسنده ,
Abstract :
We evaluated RAD001, an inhibitor of the mammalian target of rapamycin (mTOR) in human gastric cancer cell lines and determined the molecular mechanisms. RAD001 has marked growth inhibitory activity against the SNU-1 and SNU-216 cells. It inhibited phosphorylation of mTOR and S6 K, and induced G1 cell cycle arrest. Synergistic growth-inhibitory effects in combination with 5-fluorouracil (5-FU) was identified. Furthermore, RAD001 conferred sensitivity to 5-FU-resistant cell lines by downregulating thymidylate synthase (TS). In conclusion, RAD001 showed growth inhibitory activity against gastric cancer cells and acted synergistically with cytotoxic agents such as 5-FU by downregulating TS.
Keywords :
RAD001 , mTOR , Gastric cancer , thymidylate synthase
